Enterome is a clinical-stage company developing first-in-class OncoMimics immunotherapies, led by lead candidate EO2463. EO2463 is an off-the-shelf immunotherapy combining four synthetic OncoMimics peptides that mimic B‑cell markers (CD20, CD22, CD37 and CD268/BAFF receptor) plus a helper peptide (UCP2) to target malignant B lymphocytes. The approach aims to provide broad target coverage to improve safety and maximize efficacy while reducing antigen-escape driven resistance. Enterome is expanding and finalizing its Phase 1/2 SIDNEY clinical trial and preparing EO2463 for a registrational program, including a planned pivotal Phase 3 for the “watch-and-wait” iNHL population. The company has held positive interactions with regulators (FDA Type C meeting and EMA Scientific Advice) that outline a clear path to marketing authorization in watch-and-wait iNHL. New and prior clinical data (including ASCO 2024 and upcoming ICML presentation) support EO2463’s activity as monotherapy and in combination and suggest biomarker-driven identification of likely responders. Enterome leverages its understanding of the gut microbiome–immune interaction to discover and develop small molecules, proteins and peptide therapeutics for cancer, autoimmune, inflammatory and metabolic diseases. Its pipeline includes cancer immunotherapies (EO2401, EO2463), EndoMimics biologics (EM101) for inflammatory diseases, and EB8018 (sibofimloc/TAK-018), an oral FimH blocker advancing in Crohn’s disease trials. EO2401 was expected to enter Phase 1/2 trials in glioblastoma and adrenal malignancies in mid-2020, while EO2463 is being prepared as a clinical candidate for B‑cell malignancies. EB8018 is partnered globally with Takeda, with Enterome retaining a significant profit share in the US. The company has operations in Paris and Boston and is led by CEO Pierre Belichard. Enterome recently closed a €46.3M financing and drew the first tranche from a previously agreed European Investment Bank loan facility to support clinical development. Enterome is a clinical-stage biotech pioneering microbiome-derived pharmaceuticals and diagnostics targeting inflammatory bowel diseases and cancer. Its lead programs are EB8018, an oral gut‑restricted FimH blocker for Crohn’s disease, and EO2315, an immuno‑oncology candidate derived from bacterial antigens. EB8018 completed a Phase 1 trial in 2017 showing safety and minimal blood absorption and is advancing to Phase 2; EO2315 has produced strong immune responses and tumor cell‑killing ex vivo and controlled tumor growth in vivo and is entering a Phase 1b study in glioblastoma. The company is also developing the next generation of its proprietary metagenomics drug discovery platform to expand therapeutic target discovery. Enterome has established partnerships with pharmaceutical companies (including Johnson & Johnson/Janssen, Takeda, Abbvie and Bristol‑Myers Squibb) and a 50/50 joint venture with Nestlé Health Science for microbiome diagnostics. The company was founded in 2012 in Paris. Enterome Bioscience SA, based in Paris and Boston, pioneers pharmaceuticals and diagnostics derived from the gut microbiome. Its lead therapeutic candidate is EB 8018, a novel small-molecule FimH antagonist licensed from Vertex that targets Adherent Invasive Escherichia coli (AIEC) proliferation. EB 8018 is being developed as a potential treatment for inflammatory bowel diseases and acts by preventing AIEC adhesion to the gut wall to help restore a dysbiotic microbiome. The company also develops microbiome-based diagnostics for IBD and other microbiome-related diseases and seeks partnerships with diagnostic and pharmaceutical companies. Enterome intends to advance therapeutic programs in immuno-oncology alongside its diagnostics and gut-focused therapies. The company will use the recent financing to support moving EB 8018 into first clinical studies in 2016. Enterome Bioscience develops disease management solutions and diagnostic products grounded in gut microbiome science. The company is building diagnostic tools to support patient stratification, personalized therapies and the clinical development of new drugs. Target indications include microbiome-related diseases such as inflammatory bowel diseases and metabolic diseases like diabetes and obesity. Enterome intends to use newly raised funds for R&D and business development activities. Founded in 2012 and led by CEO Pierre Belichard, the company is based in Paris, France. To date it has raised a total of €17.5m.

Total raised

$195M

Funding rounds

8

Latest round

Equity

Latest activity

Jun 2025